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Pseudomonas aeruginosa, as an opportunistic pathogen, establishes a chronic infection in the respiratory track of 
patients suffering from pneumonia and bronchiectasis, including cystic fibrosis. Biofilm formation inside the oversecreted 
mucus layer lining the patient airway and production of virulence factors, a process controlled by quorum sensing, are 
considered to be the major virulence determinants in P. aeruginosa pathogenesis. Recently, an abnormally thickened 
mucus layer was proven to be anaerobic. Given the fact that currently used antibiotics are less effective under anaerobic 
environments, these new findings lead us to change the way we confront P. aeruginosa infection. This article reviews 
pathological features of patient airways that become susceptible to P. aeruginosa infection and bacterial adaptation that 
contributes to the prolonged survival inside the patient airway. 
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I. Pseudomonas aeruginosa 
 
P. aeruginosa has long been considered to be a classic 
example of an opportunistic pathogen (1). The organism 
does not normally cause infections in individuals with 
intact immune systems, but immunocompromised patients 
are particularly at risk for P. aeruginosa infection. 
P. aeruginosa, a gram-negative bacterium, is remarkably 
versatile in terms of the metabolism, and thus, can maximize 
its survival fitness in various environments including human 
hosts (2). The organism, however, is strictly dependent on 
respiration to generate energy and is often classified as a 
non-fermenting bacterium (3, 4). 
In nature, this gram-negative bacterium is found in highly 
organized communities called biofilms and has been 
served as a model organism to explore bacterial biofilm 
formation (5). Biofilm is defined as a microbial "living" 
biomass grown on an aggregate or on a surface with distinct 
architecture (6, 7). Compared to its free living counterpart 
(i.e. planktonic cells), bacteria grown as biofilm are 
refractory to a variety of antimicrobial reagents including 
H2O2 (8), a range of antibiotics (9, 10), and various heavy 
metals (11). Moreover, bacterial biofilm is more resistant to 
host immune clearance (12). 
P. aeruginosa has been notorious for its high level 
antibiotic-resistance, arguably one of the most important 
virulence features of clinically isolated P. aeruginosa. 
Recently, we reported that over 76% of the Korean 
pneumonia patients isolates showed resistance to more than 
one antimicrobial agent, currently employed to combat P. 
aeruginosa infection (Yoon et al., in press). Mechanisms 
by which P. aeruginosa acquires antibiotic-resistance have 
been extensively studied and reviewed in detail elsewhere 
(13~16). 
59 
 Received: June 8, 2010/ Revised: June 10, 2010 
Accepted: June 11, 2010 
*Corresponding author: Sang Sun Yoon, Ph.D. Department of Microbiology,
College of Medicine, Yonsei University, 250 Seongsanno, Seodaemun-gu, 
Seoul 120-752, Korea. 
Phone:  +82-2-2228-1824, Fax:  +82-2-392-7088 
e-mail:  sangsun_yoon@yuhs.ac 
 Review Article
60 SS Yoon 
 
Bacterial virulence factors are (i) molecules produced by 
microbial pathogens that induce specific disease symptoms 
in the host and (ii) mechanisms by which pathogens deliver 
(or secrete) those molecules. But, in broad terms, virulence 
factors include any factors that contribute to the successful 
colonization of host tissues. As an extracellular pathogen, 
P. aeruginosa secretes an array of virulence factors, whose 
production is controlled by quorum sensing, a cell-density 
dependent gene regulatory pathway. Effectors to be secreted 
include elastase (17, 18), alkaline protease (19, 20), 
exotoxins (21, 22), phospholipase (23, 24), and pyocyanin 
(25). These molecules exert toxic effects on human hosts 
by directly degrading host tissues or eliciting oxidative 
stress. 
 
II. Abnormal mucus environments in 
airway diseases 
 
Under normal airway environments, invading micro- 
organisms are usually expelled and/or cleared by the upper 
airway innate immune defense system that includes the 
mucociliary clearance (26~28). P. aeruginosa being an 
opportunistic pathogen, however, can cause persistent 
infection in patients with abnormal airway mucus secretion. 
Patients suffering from cystic fibrosis (CF) (1, 29), 
bronchiectasis (30, 31), and pneumonia (32) are especially 
vulnerable to P. aeruginosa infection. Among many 
pathological symptoms, aforementioned airway diseases 
are characterized with the noticeable oversecretion of 
mucus on top of the airway epithelium that debilitates the 
mucociliary clearance activity (1, 33). As depicted in 
Figure 1, mucus hypersecretion is often accompanied with 
the depletion of the periciliary liquid layer (PLL) and 
subsequent loss of mucociliary clearance activity. 
CF is a genetic disorder caused by mutations in the cystic 
fibrosis transmembrane conductance regulator (CFTR) 
gene coding for Cl- transport channel across the apical 
surface of secretory cells (34). In CF, hyperactivation of 
epithelial Na+ channel (ENaC), an event that occurs due to 
the mutation in the CFTR gene (35), drives the isotonic 
absorption of H2O and ions into the airway epithelium 
resulting in the dehydration of PLL and thus the formation 
of a stagnant mucus layer (1). Bronchiectasis (BE) is a 
disease state where the bronchial tree is irreversibly dilated. 
BE is caused by early childhood bacterial infections or 
pulmonary tuberculosis and patients with BE are highly 
susceptible to secondary infection by microbial pathogens 
including P. aeruginosa. BE is also featured with mucus 
hypersecretion and impaired mucociliary clearance activity 
(33). A recent report demonstrated that neutrophil protease 
present in large quantity in sputum samples from the BE 
patients stimulates the secretory response in tracheal 
submucosal glands (33). 
Much evidence indicated that the oversecreted and 
stationary mucus layer provides a nice "habitat" for P. 
aeruginosa to colonize and proliferate (1, 36). Importantly, 
this abnormally altered mucus layer (Fig. 1B) also renders 
the host immune system ineffective against P. aeruginosa 
Figure 1. Schematic comparison between normal (A) and 
diseased (B) airway mucus environments. Maintenance of 
periciliary liquid layer (PLL) with constant depth and appropriate 
movement of the mucus layer on top of the PLL, which mediates 
the mucociliary clearance, is achieved in normal airways. In 
diseased states, however, PLL is depleted and an abnormally 
oversecreted (and thus, highly viscous) mucus layer is formed. 
This mucus layer is highly susceptible to bacterial colonization. 
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infection. Despite a vigorous and rapid influx of neutrophils 
into the infected airways (37), accompanied by production 
of high titers of specific antibodies (38), P. aeruginosa 
infection persists and lung function progressively declines. 
Recently, the stagnant mucus layer lining the airway of 
chronic CF patients was reported to be anaerobic (3, 36). 
The lack of oxygen potential is ascribed to (i) the limited 
oxygen transport into the mucus layer due to its increased 
viscosity and (ii) a high rate of oxygen consumption by 
immune-related and airway epithelial cells. This new 
observation provides a new insight into the establishment 
of P. aeruginosa infection under anaerobic condition. 
 
 
III. Anaerobic growth of P. aeruginosa 
 
Being an obligate respirer, P. aeruginosa is also capable 
of generating energy even in the absence of oxygen using 
NO3- (nitrate) or NO2- (nitrite) as alternative electron 
acceptors (1, 4). The P. aeruginosa genome harbors clusters 
of genes encoding enzymes for anaerobic respiration. 
Figure 2 compares the electron transport pathway between 
aerobic and anaerobic growth conditions. NADH, produced 
by the glycolysis and TCA cycle, feeds an electron to the 
inner-membrane bound NADH dehydrogenase (39) to 
initiate the electron transport pathway. During the sequential 
electron transports to cytochrome bc1 complex (40) and 
Figure 2. Aerobic (A) vs. anaerobic (B) respiratory pathways in P. aeruginosa. P. aeruginosa can use either oxygen or nitrate/nitrite 
as electron acceptors in the electron transport chain. NADH DH, NADH dehydrogenase; Cyt bc1, cytochrome bc1 complex; Cyt oxidase, 
cytochrome oxidase; NAR, nitrate (NO3
-) reductase; NIR, nitrite (NO2
-) reductase; NOR, nitric oxide reductase; N2OR, nitrous oxide 
(N2O) reductase. 
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cytochrome oxidase (41), H+ ions are pumped out across 
the inner membrane generating pH gradient. Then, H+ ions 
re-enter the cytoplasm via ATP synthase (42) to produce 
ATP. 
As shown in Figure 2B, pH gradient across the inner 
membrane can still be generated when NO3- or NO2- is 
supplemented even under the anaerobic condition. Anaerobic 
respiration, often called denitrification (4) involves four 
reduction steps from NO3- to N2. Each step is mediated by 
respiratory enzymes; nitrate reductase (NAR), nitrite 
reductase (NIR), nitric oxide reductase (NOR), and nitrous 
oxide reductase (N2OR). It is of interest to note that NO, a 
toxic chemical to microorganisms (4), is produced as a 
byproduct during the denitrification process. This is 
analogous to the unavoidable production of reactive oxygen 
species in aerobically respiring cells. P. aeruginosa, however, 
can minimize the accumulation of the toxic NO during the 
anaerobic growth by the activity of NOR (4). 
Importantly, NO3- and NO2- were detected in larger 
quantity in sputum or exhaled condensate of patients with 
pulmonary exacerbation of CF than those obtained from 
normal individuals (43, 44). This result suggests that P. 
aeruginosa proliferates well inside the anaerobic mucus 
layer exploiting the compounds produced by the host and 
may provide an insight into why P. aeruginosa has been 
such a competitive colonizer in the patient airways. 
 
IV. P. aeruginosa biofilm and a new emerged 
concept on the enhanced biofilm formation 
during anaerobic respiration 
 
Biofilm formation is often described as a process by 
which bacterial cells develop into a sessile community (45). 
Steps that can be clearly distinguished during this process 
include (i) initial attachment of free living bacteria to 
abiotic or biotic surface (46), (ii) microcolony formation 
with ensuing cell division (47), (iii) secretion of matrix 
molecules and growth of microcolonies into macrocolony 
(48), and (iv) differentiation into mature biofilm with 
3-dimensional architecture (5). 
Biofilm formation has been a major problem due to its 
resistance to a variety of antimicrobial treatments. Molecular 
basis that accounts for such a high-level resistance has 
been extensively studied. Recently, a role of periplasmic 
glucan encoded by the ndvB gene has been proposed to 
explain the antibiotic resistance of P. aeruginosa biofilm 
(49, 50). While a mutant defective in ndvB can form biofilms 
with normal structural features, the mutant exhibited 
enhanced sensitivity to tobramycin, an aminoglycoside-
type antibiotic. It was also found that the mutant strains 
showed decreased binding to tobramycin, suggesting that 
periplasmic glucan may provide a physical barrier to prevent 
tobramycin from penetrating into the cytoplasm. 
Recently, it was revealed that P. aeruginosa forms more 
robust biofilm during anaerobic respiration than they do 
when they respire aerobically (3). Since oxygen transfer to 
the depth of biofilm can be significantly limited (51), it has 
been postulated that "anaerobic" local regions may exist 
within mature biofilms. This result, however, shows that 
P. aeruginosa is actively responding to the anaerobic 
respiration in order to form more robust biofilm, a resistant 
mode of growth. This result further suggests that P. 
aeruginosa airway infection is clearly associated with the 
biofilm formation under anaerobic conditions. Understanding 
the molecular basis behind this anaerobiosis-induced robust 
biofilm formation will provide better insight into the P. 
aeruginosa pathogenic mechanisms leading us to come up 
with novel strategies to treat the infection. 
 
V. P. aeruginosa quorum sensing and the 
future direction 
 
P. aeruginosa fine-tunes its virulence by a process of 
inter-cellular communication known as quorum sensing 
(QS). In QS, P. aeruginosa produces, secretes, and responds 
to extracellular signal molecules, called autoinducers, to 
regulate the expression of genes involved in biofilm 
formation (52) and production of diverse virulence factors 
including exotoxin A (53), elastase (54), alkaline protease 
(55), rhamnolipid (54), and pyocyanin (25). Expression of 
genes encoding superoxide dismutase and catalase, which 
mediate oxidative stress responses, is also controlled by QS 
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(56). The role of QS in P. aeruginosa virulence was clearly 
demonstrated in studies using infection models with a 
range of different living hosts (57~59) and cultured host 
cells (60, 61). 
There are three well-characterized QS systems in P. 
aeruginosa: las, rhl, and pqs. The las and rhl systems were 
initially identified to be essential for elastase and 
rhamnolipid production, respectively (62, 63). Each system 
is composed of its own transcriptional activator protein 
(LasR or RhlR) and cognate autoinducer synthase, LasI or 
RhlI, that produces N-(3-oxododecanoyl)-L-homoserine 
lactone and N-butyryl-L-homoserine, respectively. Each 
autoinducer molecule binds to its cognate transcriptional 
activator, LasR or RhlR, and this complex then apparently 
binds to RNA polymerase, which results in transcriptional 
activation of QS regulated genes. 
Another arm of P. aeruginosa QS is a system where the 
DNA-binding affinity of MvfR (PqsR), an important 
virulence-associated transcriptional regulator, is enhanced 
upon binding with pseudomonas quinolone signal (PQS) 
(64, 65). Mounting evidence indicated that PQS is also a 
major player in the complex intertwined P. aeruginosa QS 
network and PQS-mediated QS is therefore required for the 
uninterrupted production of elastase (66) and rhamnolipid 
(67, 68). 
Recently, many CF isolates were recovered that harbor 
mutations in lasR gene (69, 70). This fining is contradictory 
to the established knowledge that lasR-associated QS plays 
an essential role in P. aeruginosa virulence. Subsequent 
study, however, reported that mutations in lasR confer 
increased survival fitness in CF airways, where bacteria 
shift its energy metabolism to anaerobic respiration (71). 
This result further suggests that infection dynamics inside 
the patient airway are highly complicated and roles of QS in 
P. aeruginosa pathogenesis in vivo have to be re-evaluated. 
Interestingly, QS mutants, in which lasR gene or rhlR 
gene is disrupted, lost viability during in vitro biofilm 
formation under anaerobic respiration, a phenomenon due 
to the overproduction of toxic nitric oxide (NO), a byproduct 
of anaerobic respiration (3). This suggests that QS is 
required to maintain viability during anaerobic biofilm 
formation supporting the presence of a novel function of P. 
aeruginosa QS. Further investigation is warranted to better 
understand the QS operation during anaerobic growth, a 
mode of proliferation that occurs in the patient airway. 
 
VI. Conclusions 
 
Although patient airways are equally exposed to diverse 
bacterial pathogens, P. aeruginosa has been a major 
microorganism that successfully colonizes and establishes 
persistent infection in the airway. P. aeruginosa airway 
infection should now be approached as an anaerobic disease 
of lung and this new idea necessitates further research 
directed on identifying new targets, inhibition of which will 
decrease bacterial virulence or survival under anaerobic 
condition. Because biofilm and QS are two major arms of 
virulence mechanisms of this clinically important pathogen, 
future therapeutic strategies for the treatment of airway 
infection should include molecular-level understanding of 
anaerobiosis-induced biofilm and QS. 
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